{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:38:07Z","timestamp":1790127487403,"version":"4.0.1"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019725","name":"DEBRA Austria","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100019725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite a significant rise in the incidence of cutaneous squamous cell carcinoma (SCC) in recent years, most SCCs are well treatable. However, against the background of pre-existing risk factors such as immunosuppression upon organ transplantation, or conditions such as recessive dystrophic epidermolysis bullosa (RDEB), SCCs arise more frequently and follow a particularly aggressive course. Notably, such SCC types display molecular similarities, despite their differing etiologies. We leveraged the similarities in transcriptomes between tumors from organ transplant recipients and RDEB-patients, augmented with data from more common head and neck (HN)-SCCs, to identify drugs that can be repurposed to treat these SCCs. The in silico approach used is based on the assumption that SCC-derived transcriptome profiles reflect critical tumor pathways that, if reversed towards healthy tissue, will attenuate the malignant phenotype. We determined tumor-specific signatures based on differentially expressed genes, which were then used to mine drug-perturbation data. By leveraging recent efforts in the systematic profiling and cataloguing of thousands of small molecule compounds, we identified drugs including selumetinib that specifically target key molecules within the MEK signaling cascade, representing candidates with the potential to be effective in the treatment of these rare and aggressive SCCs.<\/jats:p>","DOI":"10.3390\/ijms23021007","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:46:03Z","timestamp":1642452363000},"page":"1007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Transcriptome-Guided Drug Repurposing for Aggressive SCCs"],"prefix":"10.3390","volume":"23","author":[{"given":"Roland","family":"Zauner","sequence":"first","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wimmer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Dorfer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ablinger","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-1789","authenticated-orcid":false,"given":"Ulrich","family":"Koller","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-9031","authenticated-orcid":false,"given":"Josefina","family":"Pi\u00f1\u00f3n Hofbauer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-5068","authenticated-orcid":false,"given":"Christina","family":"Guttmann-Gruber","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"},{"name":"Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-3890","authenticated-orcid":false,"given":"Verena","family":"Wally","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin Cancers in Organ Transplant Recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am. J. Transpl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/jcm4061229","article-title":"Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients","volume":"4","author":"Chockalingam","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","article-title":"Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens","volume":"40","author":"Jensen","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ctrv.2013.08.005","article-title":"Papillomavirus-associated squamous skin cancers following transplant immunosuppression: One Notch closer to control","volume":"40","author":"Connolly","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-016-0489-9","article-title":"Inherited epidermolysis bullosa and squamous cell carcinoma: A systematic review of 117 cases","volume":"11","author":"Chiaverini","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjd.19421","article-title":"Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bull-osa-associated cutaneous squamous cell carcinoma","volume":"184","author":"Dayal","year":"2021","journal-title":"Br. J. Derm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1155\/2011\/153108","article-title":"TGF\u03b2-signaling in squamous cell carcinoma occur-ring in recessive dystrophic epidermolysis bullosa","volume":"34","author":"Knaup","year":"2011","journal-title":"Anal. Cell. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine in-duces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/mc.20744","article-title":"Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epitheli-al-mesenchymal transition: Role of TGF\u03b2 signaling pathway","volume":"50","author":"Walsh","year":"2011","journal-title":"Mol. Carcinog."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Condorelli, A.G., Dellambra, E., Logli, E., Zambruno, G., and Castiglia, D. (2019). Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225707"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"djv293","DOI":"10.1093\/jnci\/djv293","article-title":"Suppression of TGF\u03b2 and Angiogenesis by Type VII Collagen in Cutaneous SCC","volume":"108","author":"Martins","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging","volume":"78","author":"Que","year":"2018","journal-title":"J. Am. Acad. Derm."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Persechino, F., Ranieri, D., Guttieri, L., Nanni, M., Torrisi, M., and Belleudi, F. (2021). Expression Profile of Fibroblast Growth Factor Receptors, Keratinocyte Differentiation Markers, and Epithelial Mesenchymal Transition-Related Genes in Actinic Keratosis: A Possible Predictive Factor for Malignant Progression?. Biology, 10.","DOI":"10.3390\/biology10040331"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/jid.2010.243","article-title":"No Evidence That Human Papillomavirus Is Responsible for the Aggressive Nature of Recessive Dystrophic Epidermolysis Bullosa\u2013Associated Squamous Cell Carcinoma","volume":"130","author":"Purdie","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jid.2018.04.026","article-title":"Reduced Microbial Diversity Is a Feature of Recessive Dystrophic Epidermolysis Bullosa-Involved Skin and Wounds","volume":"138","author":"Fuentes","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eaas9668","DOI":"10.1126\/scitranslmed.aas9668","article-title":"APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epi-dermolysis bullosa","volume":"10","author":"Cho","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pathol.2019.10.008","article-title":"Human papilloma virus related squamous cell carcinomas of the head and neck: Diagnosis, clinical implications and detection of HPV","volume":"52","author":"Paver","year":"2019","journal-title":"Pathology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41388-018-0657-6","article-title":"APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma","volume":"38","author":"Cannataro","year":"2019","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1038\/onc.2011.180","article-title":"Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma","volume":"30","author":"Watt","year":"2011","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"D431","DOI":"10.1093\/nar\/gkz1023","article-title":"LINCS Data Portal 2.0: Next generation access point for perturbation-response signatures","volume":"48","author":"Stathias","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hameetman, L., Commandeur, S., Bavinck, J.N.B., Wisgerhof, H.C., De Gruijl, F.R., Willemze, R., Mullenders, L., Tensen, C.P., and Vrieling, H. (2013). Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-58"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/CCI.19.00119","article-title":"Mul-tiomic Integration of Public Oncology Databases in Bioconductor","volume":"4","author":"Ramos","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/npjsba.2016.15","article-title":"L1000CDS2: LINCS L1000 characteristic direction signatures search engine","volume":"2","author":"Duan","year":"2016","journal-title":"NPJ Syst. Biol. Appl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-021-00281-0","article-title":"MEK inhibitors\u2014Novel targeted therapies of neurofibromatosis associated benign and malignant lesions","volume":"9","author":"Harder","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/0008-5472.CAN-12-4539","article-title":"VEGF-C and VEGF-D Blockade Inhibits Inflammatory Skin Carcinogenesis","volume":"73","author":"Alitalo","year":"2013","journal-title":"Cancer Res."},{"key":"ref_26","first-page":"227","article-title":"Anti-angiogenic Targets: Angiopoietin and Angiopoietin Receptors","volume":"24","author":"Kiss","year":"2020","journal-title":"Tumor Angiogenesis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1038\/s41388-019-0773-y","article-title":"PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma","volume":"38","author":"Peguera","year":"2019","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-4632.2010.04846.x","article-title":"Greater expression of TC21\/R-ras2 in highly aggressive malignant skin cancer","volume":"50","author":"Lee","year":"2011","journal-title":"Int. J. Derm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1038\/sj.onc.1209494","article-title":"AURKA is one of the downstream targets of MAPK1\/ERK2 in pancreatic cancer","volume":"25","author":"Furukawa","year":"2006","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug Repurposing for Rare Diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fania, L., Didona, D., Di Pietro, F., Verkhovskaia, S., Morese, R., Paolino, G., Donati, M., Ricci, F., Coco, V., and Ricci, F. (2021). Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020171"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1074-5521(99)80088-X","article-title":"Paradoxical activation of Raf by a novel Raf inhibitor","volume":"6","author":"Eyers","year":"1999","journal-title":"Chem. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12348","DOI":"10.1038\/ncomms12348","article-title":"Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.14104","article-title":"Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: Best clinical practice guidelines","volume":"174","author":"Mellerio","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_36","first-page":"448","article-title":"Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab","volume":"17","author":"Medek","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_37","first-page":"319","article-title":"Current advances and perspectives in the treatment of advanced melanoma","volume":"10","author":"Livingstone","year":"2012","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cell.2016.03.045","article-title":"A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling","volume":"165","author":"Dutta","year":"2016","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-18-2661","article-title":"Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma","volume":"25","author":"Atanasova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_41","first-page":"1","article-title":"Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing","volume":"10","author":"Onoufriadis","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1515057","DOI":"10.1080\/2162402X.2018.1515057","article-title":"Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma","volume":"8","author":"Kang","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87124","DOI":"10.18632\/oncotarget.13547","article-title":"Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer","volume":"7","author":"Hu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403269","article-title":"Downmodulation of ERK protein kinase activity inhibits VEGF secrection by human myeloma cells and myeloma-induced angiogenesis","volume":"18","author":"Giuliani","year":"2004","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1038\/s41598-021-84044-9","article-title":"Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach","volume":"11","author":"Imami","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2174\/1386207323666201027120149","article-title":"Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning","volume":"24","author":"Liu","year":"2021","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/517109a","article-title":"Programming tools: Adventures with R","volume":"517","author":"Tippmann","year":"2015","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"EdgeR: A Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav. Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: A comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/bioinformatics\/btt285","article-title":"Pathview: An R\/Bioconductor package for pathway-based data integration and visualization","volume":"29","author":"Luo","year":"2013","journal-title":"Bioinformatics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/2\/1007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:02:53Z","timestamp":1760133773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/2\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23021007"],"URL":"https:\/\/doi.org\/10.3390\/ijms23021007","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}